The potency and selectivity index of the AZTphenyl phosphate derivatives in thymidine kinase (TK)-deficient T cells were substantially enhanced by introducing a single para-bromo substituent in the phenyl moiety. AZT-5′-(p-bromophenyl methoxyalaninyl phosphate) was 43fold more potent than AZT-5′-(phenyl methoxyalaninyl phosphate) and was fivefold more potent than AZT in inhibiting human immunodeficiency virus (HIV) replication in TKdeficient CEM cells.
The 5′-triphosphates of 2′,3′-dideoxynucleoside (ddN) analogues, which are generated intracellularly by the action of nucleoside and nucleotide kinases, are potent inhibitors of human immunodeficiency virus (HIV) reverse transcriptase (RT) (Furman et al., 1986; Balzarini et al., 1989; Hao et al., 1988) . The rate-limiting step for the conversion of 3′-azido-3′-deoxythymidine (zidovudine; AZT) to its bioactive metabolite AZT-triphosphate seems to be the conversion of the monophosphate derivative to the diphosphate derivative, whereas the rate-limiting step for the intracellular generation of the bioactive 2′,3′-dideoxy-2′,3′-didehydrothymidine (stavudine; d4T) metabolite d4T-triphosphate was reported to be the conversion of the nucleoside to its monophosphate derivative (Balzarini et al., 1989; McGuigan et al., 1996) . In an attempt to overcome the dependence of ddN analogues on intracellular nucleoside kinase activation, McGuigan and coworkers have prepared aryl methoxyalaninyl phosphate derivatives of AZT (McGuigan et al., 1992 and d4T (McGuigan et al., 1992 (McGuigan et al., , 1993 (McGuigan et al., , 1996a . Such compounds have been shown to undergo intracellular hydrolysis to yield monophosphate derivatives that are further phosphorylated by thymidylate kinase to give the bioactive triphosphate derivatives in a thymidine kinase (TK)-independent fashion (McGuigan et al., 1996; McIntee et al., 1997) . However, all attempts to date to further improve the potency of the aryl phosphate derivatives of d4T by various substitutions of the aryl moiety without concomitantly enhancing their cytotoxicity have failed (McGuigan et al., 1996) .
We have recently reported that the potency and selectivity index of the phenyl methoxyalaninyl phosphate derivative of d4T [but not 3-deoxythymidine (3dT)] against human immunodeficiency virus (HIV) in TK-deficient CEM T cells can be substantially enhanced by introducing a single para-bromo substituent in the phenyl moiety (Vig et al., 1998a,b) . Subsequent studies have shown that a mono-bromo substitution at the para position of the phenyl moiety in the phenyl methoxyalaninyl phosphate derivative of d4T enhances the ability of the phenyl methoxyalaninyl derivative of d4T to undergo hydrolysis. This is owing to the electron withdrawing property of the bromo substituent and results in the generation of substantially higher quantities of the key metabolite alaninyl-d4T monophosphate in TK-deficient CEM T cells (Venkatachalam et al., 1998) . The purpose of the present study was to examine the anti-HIV activity of the mono-bromo-substituted phenyl phosphate derivative of AZT.
Here, we report the identification of the para-bromo substituted phenyl methoxyalaninyl phosphate derivative of AZT as an active anti-HIV agent which potently inhibits HIV replication in peripheral blood mononuclear cells PBMC from HIV-negative donors and TK-deficient CEM T cells were cultured for 72 h in RPMI 1640 supplemented with 20% (v/v) heat-inactivated FBS, 3% IL-2, 2 mM L-glutamine, 25 mM HEPES, 2 g/l NaHCO 3 , 50 µg/ml gentamicin (plus 4 µg/ml PHA for PBMC only) prior to exposure to HIV-1 at an m.o.i. of 0.1 during a 1 h adsorption period at 37°C in a humidified 5% CO 2 atmosphere. Subsequently, cells were cultured in 96-well microtitre plates (100 µl/well; 2×10 6 cells/ml, triplicate wells) in the presence of various inhibitor concentrations and aliquots of culture supernatants were removed from the wells on the 7th day after infection for RT assays using a commercially available assay kit (Amersham) as previously described (Erice et al., 1993; Uckun et al., 1998; Zarling et al., 1990) . This radioenzyme assay uses a DNA/RNA primer/template attached to scintillant-filled fluomicrospheres. Incorporation of radiolabelled nucleotides by reverse transcription results in extension of the primer and stimulation of the scintillant within the microspheres. The resulting signals are detected by a scintillation counter and recorded as c.p.m. Percentage viral inhibition is calculated by comparing c.p.m. from the test substance-treated infected cells with c.p.m. from untreated infected cells (virus controls) and untreated uninfected cells (cell controls). In parallel, the effects of various treatments on cell viability were also examined, as described . In brief, non-infected PBMC were treated with each compound for 7 days under identical experimental conditions. A microculture tetrazolium assay (MTA), using XTT, was performed to quantify cellular proliferation. All data are in µM and represent IC 50 values measured by RT activity and MTA assays. The values for minimum (SI) were determined using the formula SI = IC 50 [MTA] / IC 50 [RT].
(PBMC) as well as TK-deficient CEM T cells without any detectable cytotoxicity. To our knowledge, this is the first report of a previously unappreciated structure-activity relationship determining the potency of phenyl phosphate derivatives of AZT. Further development of AZT-5′-(parabromophenyl methoxyalaninyl phosphate) may provide the basis for the design of effective HIV treatment strategies capable of inhibiting HIV replication in TK-deficient cells. AZT 3 was prepared from thymidine using a method described previously (Chu et al., 1989) . Compounds 1 and 2 were prepared by phosphorylating the C-5′ hydroxy group of AZT 3. The phosphorylation agents possessing the unsubstituted phenyl and p-bomo substituted phenyl moieties 5a and 5b were prepared from commercially available corresponding phenols in two steps according to the method reported by McGuigan et al. (1993) (Figure 1a ). Figure 1(b) shows the synthesis of 1 and 2 by reacting AZT with their corresponding phosphorylation agents 5a and 5b, respectively. Compounds 4b, 5b and 2 were previously described (McGuigan et al., 1993) . Compounds 4a, 5a and 1 are new compounds and a description of their synthesis and characterization is included in this paper.
Compounds 1, 2 and the parent compound AZT 3 were tested for their ability to inhibit HIV replication in TKdeficient CEM T cells as well as PBMC using previously described procedures (Table 1) (Zarling et al., 1990; Erice et al., 1993; Uckun et al., 1998) . Percentage inhibition of viral replication was calculated by comparing the RT activity values for the test substance-treated infected cells with those for untreated infected cells. In parallel, the cytotoxicity of the compounds was examined using a microculture tetrazolium assay (MTA) of cell proliferation . In brief, AZT 3 was less effective in TK-deficient CEM cells than in PBMC in inhibiting HIV-1 replication (Table 1) . Unlike the corresponding d4T derivatives (Vig et al., 1998) , the unsubstituted phenyl phosphate derivative of AZT 2 was not more potent than the parent compound AZT 3. However, the para-bromo substituted phenyl phosphate derivative of AZT, AZT-5′-(para-bromophenyl methoxyalaninyl phosphate) 1, was more effective than AZT in inhibiting HIV replication in TK-deficient CEM cells (IC 50 [RT] values 0.04 µM and 0.1-0.2 µM, respectively) and its potency was similar to that of AZT in PBMC. Compound 1 did not exhibit any detectable cytotoxicity against PBMC or CEM cells at concentrations as high as 100 µM, as determined by MTA. The selectivity index (SI) values for compound 1 and AZT were similar in PBMC, but they were better for compound 1 in TK-defi-cient CEM T cells. Compound 1 was more potent than AZT 3 and 2 in inhibiting HIV replication of TK-deficient CEM cells. The dose-dependent inhibition of p24 HIV-1 core antigen production and HIV-1 RT activity in HIV(HTLV IIIB )infected TK-deficient CEM T cells and PBMC by compound 1 is illustrated in Figure 2 In in vitro esterase hydrolysis, 500 nmols of compounds 1 or 2 were incubated with 40 U of porcine liver esterase in 0.5 ml Tris-HCl buffer (pH 7.4) for 1 h at 37 °C. The reaction was terminated by addition of 0.25 ml acetone. After removing the precipitated protein, 100 µl of the supernatant was subjected to analytical HPLC for determination of the amounts of A-AZT-MP and AZT-MP generated by the enzymatic hydrolysis. In in vitro hydrolysis, 10×10 6 CEM cells (10×10 6 /ml in RPMI, 10% fetal bovine serum, 1% penicillin/streptomycin) were incubated with 100 µM compound 1 or compound 2 for 3 hrs at 37 °C. After incubation, cells were washed twice in ice-cold PBS and extracted by addition of 0.5 ml of 60% methanol. Cell lysates were kept at -20 °C overnight, after which lysates were centrifuged at 15,000 × g for 10 min to remove the cell debris. One hundred microlitre aliquots of these samples were subjected to analytical HPLC for detection of A-AZT-MP, AZT-MP, and AZT. The HPLC system consisted of a Hewlett Packard 1100 series instrument equipped with a quaternary pump, an autosampler, an electronic degasser, a diode array detector and a computer with a Chemstation software program for data analysis. The samples were eluted on a 250×4.6 mm Zorbox SB-C18 column. A solvent gradient was utilized to resolve the metabolite from the parent compound, which consisted of a mixture of acetonitrile and 10 mM ammonium phosphate buffer (pH 3.7). The gradient ran at a flow rate of 1 ml/min from 5 to 18% acetonitrile for the first 8 min, kept at 18% acetonitrile for 8-12 min, and finished with a linear gradient from 18% to 100% in the next 20 min. The detection wavelength was set at 270 nm. A major metabolite peak with a retention time of 10 min corresponding to A-AZT-MP was detected primarily in aliquots from lysates of CEM cells treated with compound 1. be attributed to the para-bromo substituent in the phenyl moiety, which is likely to enhance its ability to undergo hydrolysis (B to C in Figure 3a ) due to the electron withdrawing property of the bromo substituent (Figure 3b ). This may result in generation of substantially higher quantities of the key metabolite AZT-monophosphate in the TK-deficient CEM T cells (Figure 3a ). We incubated CEM cells with compounds 1 and 2 (100 µM) for 3 h to compare the formation of the partially hydrolysed phosphate diester metabolite, alaninyl AZT monophosphate (A-AZT-MP), by HPLC. Notably, the amount of this metabolite in CEM cells treated with compound 1 was more than 10-fold greater than in CEM cells treated with compound 2 (Figure 4 , Table 2 ). Similarly, treatment of compound 1 with porcine liver esterase yielded >100-fold greater amounts of A-AZT-MP than the treatment of compound 2 (Table 2) . To our knowledge, this is the first demonstration that the potency as well as SI of the AZT-phenyl phosphate derivatives in TK-deficient T cells can be substantially enhanced by introducing a single para-bromo substituent in the phenyl moiety. This previously unknown structureactivity relationship determined by the phenyl moiety of the phosphate derivatives of AZT may provide the basis for the design of potentially more potent AZT analogues. The therapeutic potential of compound 1 needs to be evaluated in detailed preclinical in vivo toxicity, pharmacokinetics and efficacy studies.
Synthetic procedures and characterization data p-Bromophenyl phosphorodichloridate 4a
Following the procedure described by McGuigan et al. (1993) , a solution of p-bromophenol (13.20 g; 76.30 mmol) and distilled triethylamine (10.65 ml) in anhydrous Et 2 O (165 ml) was added dropwise into a vigorously stirred solution of phosphoryl chloride (8.5 ml; 91.2 mmol) in anhydrous Et 2 O (83 ml) at 0°C over a period of 3 h under nitrogen atmosphere. Subsequently, the resultant mixture was gradually warmed up to room temperature, stirred efficiently overnight at room temperature and then heated to reflux for 2 h. The reaction mixture was cooled to room temperature and filtered under aspirator pressure. The precipitate was washed with anhydrous Et 2 O (2×50 ml). The combined Et 2 O layers were evaporated to dryness on a rotary evaporator to yield crude 4a as a pale yellow oil which was then subjected to vacuum distillation to give pure 4a (14.05 g; 63.5 % yield) as a colourless viscous oil (b.p. 110-115°C/267 Pa). IR (Neat) 3095, 1481, 1303, 1187, 948, 829 cm -1 
p-Bromophenyl methoxyalaninyl phosphorochloridate 5a
Following the procedure described by McGuigan et al. (1993) , a solution of distilled triethylamine (8.80 ml; 63.14 mmol) in anhydrous CH 2 Cl 2 (180 ml) was added dropwise via an addition funnel into a vigorously stirred solution of p-bromophenyl phosphorodichloridate 4a (8.69 g; 29.97 mmol) and L-alanine methyl ester hydrochloride (4.19 g; 30.02 mmol) in anhydrous CH 2 Cl 2 (250 ml) at -70°C over a period of 3 h under nitogen atmosphere. Subsequently, the resultant mixture was allowed to gradually warm up to room temperature and stirred overnight at room temperature. The solvent was removed on a rotary evaporator. Anhydrous Et 2 O (300 ml) was added to dissolve the residue and then filtered under aspirator pressure to remove the white solid. The white solid was rinsed with anhydrous Et 2 O (2×60 ml). The Et 2 O layers were combined and evaporated to dryness to afford a quantitative yield of 5a (10.7 g) as a pale pink-yellow viscous oil. This product was then used for the next step reaction without further purification. IR (neat) 3212, 2989, 2952, 1747, 1483, 1270, 1209, 1147, 927, 831, 757cm -1 3′-Azidothymidine 5′-(p-bromophenyl methoxyalaninyl phosphate) 1
To a solution of 3′-azidothymidine 3 (2.227 g; 8.30 mmol) in anhydrous THF (55 ml), we added first N-methylimidazole (3.50 ml; 49.8 mmol), then p-bromophenyl methoxyalaninyl phosphorochloridate 5a (8.930 g; 25.04 mmol) in anhydrous THF (18 ml). The resultant reaction mixture was stirred vigorously at room temperature under nitrogen atmosphere in the dark. Progress of the reaction was monitored by TLC (silica gel, 5% MeOH in CHCl 3 ).
The reaction was complete after 48 h of stirring and the THF was removed on a rotary evaporator. CHCl 3 (250 ml) was added to dissolve the residue. Then the CHCl 3 solution was washed with 1.0 M aqueous HCl solution (2×200 ml), H 2 O (2×200 ml), saturated aqueous NaHCO 3 solution (2×200ml), H 2 O (1×200 ml) and brine (1×200 ml). The organic layer was dried over anhydrous Na 2 SO 4 and evaporated to dryness to afford crude 1 as a pale-yellow viscous oil. Purification of the crude product was conducted by column chromatography (silica gel 60, 230-400 mesh; eluant: 1.2% to 2.5% MeOH/CHCl 3 ) to give pure 1 (4.65 g; 95%) as a nearly colourless and viscous oil. IR (KBr) 3205.7, 3066.3, 2954.5. 2109.8, 1745.3, 1691.3, 1484.9, 1270.9, 1153.2, 1010 .5 and 926.1 cm -1 . 1 H NMR (300 MHz, CDCl 3 ) δ 8.69 (1H, br, 3-NH), 7.45 (2H, d, J 9.0 Hz, aryl H), 7.34 and 7.32 (1H, s and s, vinyl H), 7.11 (2H, d, J 9.0 Hz, aryl H), 6.18 and 6.13 (1H, t and t, J 6.6 and 6.6 Hz, H at C-1′), 4.44-3.77 (6H, m, H at C-3′, 4′ and 5′, Ala-NH and Ala-CH), 3.73 and 3.72 (3H, s and s, -COOCH 3 ), 2.51-2.20 (2H, m, H at C-2′), 2.18 (3H, s, -CH 3 at C-5), 1.39 and 1.36 (3H, d and d, Ala-CH 3 ). 13 C NMR (75 MHz, CDCl 3 ) δ 173. 6, 163.6, 150.1, 149.2, 149.1, 135.2, 132.4, 121.6, 117.8, 111.1, 85.0, 84.7, 81.9, 81.8, 65.5, 60.1, 59.9, 52.4, 50.0, 49.9, 36.9, 20.6, 20.5, 12. 2. MS (CI, m/e) 589.1 (M + , 81 Br) and 587.1 (M + , 79 Br).
